Literature DB >> 7119439

Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event.

P Katz, A M Zaytoun, J H Lee, R S Panush, S Longley.   

Abstract

The natural killer (NK) cell activity in fifteen systemic lupus erythematosus (SLE) patients was investigated by employing 51-chromium- (51Cr) release microcytotoxicity and single cell cytotoxicity assays against K562 target cells. Although the SLE patients as a group had depressed NK function in the 51Cr-release assay compared to normal subjects (p less than 0.005), those with clinically active disease displayed the greatest impairment in this activity (p less than 0.001). Active SLE patients were deficient in overall NK activity (Vmax) (p less than 0.005) but had normal percentages of potentially cytotoxic target binding cells (TBC). These TBC, however, were unable to normally kill bound target cells (p less than 0.01), which is indicative of a deficiency of "active" NK cells (p less than 0.005). Those NK cells with intact cytotoxic capabilities could "recycle" and repeat the lytic sequence normally. Exposure of normal lymphocytes to SLE sera did not impair any phase of NK function. These studies indicate that defective NK activity in SLE is secondary to an abnormality in the lytic event itself and is not due to a deficiency of NK cells, an abnormality in target binding, or an inability of NK cells to lyse multiple targets. Additionally, serum factors do not appear to play a major etiologic role in the cytotoxic abnormalities of these patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7119439

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis.

Authors:  M Grazia Cifone; R Giacomelli; G Famularo; R Paolini; C Danese; T Napolitano; A Procopio; A M Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

2.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

3.  The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody.

Authors:  M Blank; B Sredni; M Albeck; E Mozes; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

4.  Cloning and chromosomal assignment of a human cDNA encoding a T cell- and natural killer cell-specific trypsin-like serine protease.

Authors:  H K Gershenfeld; R J Hershberger; T B Shows; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

5.  Impaired release of natural killer cytotoxic factor in patients with primary Sjögren's syndrome.

Authors:  B K Pedersen; P Oxholm
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

Review 6.  The human NK cell--a short over-view and an hypothesis on NK recognition.

Authors:  M Jondal
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

7.  Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.

Authors:  M R J Green; A S M Kennell; M J Larche; M H Seifert; D A Isenberg; M R Salaman
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

8.  Natural killer cell-mediated activity in mixed connective tissue disease and its response to induction by interleukin-2.

Authors:  R González-Amaro; J Alcocer-Varela; E Martínez-Cordero; D Alarcón-Segovia
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

9.  Defective natural-killer- and killer-cell activity associated with increased polymorphonuclear leukocyte adherence in psoriasis.

Authors:  S Majewski; M Wasik; S Jabłońska; M Kamiński; M Fraczykowska
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

10.  Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient.

Authors:  A Vidaller; F Guadarrama; L Llorente; J B Méndez; F Larrea; A R Villa; D Alarcón-Segovia
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.